Evotec SE — Regulatory Filings 2016

Apr 26, 2016

News Details

Corporate | 26 April 2016 07:30

Evotec and ex scientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics

DGAP-News: Evotec AG / Key word(s): Alliance

2016-04-26 / 07:30
The issuer is solely responsible for the content of this announcement.

---

Hamburg, Germany, Dundee, UK - 26 April 2016: Evotec AG (Frankfurt Stock
Exchange: EVT, TecDAX, ISIN: DE0005664809) and ex scientia Ltd (Dundee, UK)
today announced a collaboration with the objective to discover and develop
first-in-class bispecific small molecule immuno-oncology therapies. Ex
scientia will contribute its unique algorithmic design platform while
Evotec, mainly through its Toulouse site, will be responsible for medicinal
chemistry, in vitro and in vivo pharmacology as well as development
capabilities and expertise.

Application of bispecific small molecules is an exciting strategy to
significantly expand and enhance efficacy beyond conventional single target
therapies. The initial focus will be cancer-related adenosine targets which
are increasingly recognised to play important roles in immuno-oncology.
Combining adenosine-based mechanisms with related targets holds great
promise in boosting efficacy and addressing larger patient populations
through a single small molecule drug.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented:
"Polypharmacy is a widely used strategy to manage diseases more
effectively. Ex scientia has built an outstanding platform to purposely
design bispecific small molecules that can address multiple targets through
a single molecule. Together we are well positioned to discover and develop
a new generation of small molecule immuno-oncology therapies."

Commenting on the relationship, Andrew Hopkins, CEO, ex Scientia, said:
"This is an ideal partnership to develop an innovative immuno-oncology
portfolio where our focus is on delivering efficacious drug candidates to
tackle the inherent challenges of the complex biology. Evotec have an
excellent track record in project delivery and their proven track record in
regarding efficiency gains in drug discovery chime with our own."

This is a co-owned, risk-shared-partnership, no further financial details
were disclosed.

ABOUT EX SCIENTIA LTD
ex scientia Ltd is a privately owned company developing new medicines for a
wide range of human diseases where improved efficacy is required. ex
scientia is the first company to develop a systematic algorithmic discovery
platform to automatically design molecules to complex target product
profiles. ex scientia has successfully applied its algorithm-driven design
principles to developed novel molecules with complex bispecifics, and
phenotypic product profiles. Adopting this strategy increases the
efficiency and effectiveness of drug discovery. As the industry pioneer of
automated drug design, ex scientia aims to create exceptional value for its
partners, by delivering effective treatments to the clinic. For additional
information please go to www.exscientia.co.uk.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute).The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes,
with Pfizer in the field of organ fibrosis and with Second Genome in the
field of inflammatory diseases. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

Contact ex scientia Ltd:
Dr Mark Swindells, COO, Phone: +44 (0)1382 202136, contact@exscientia.co.uk
www.exscientia.co.uk

---

2016-04-26 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX

 End of News    DGAP News Service